PropertyValue
?:definition
  • A group of subjects in a phase I trial, usually accrued after the maximum tolerated dose maximum tolerated dose has been established. These subjects, often with additional eligibility criteria, are used to: confirm that a safe level of drug exposure has been established, obtain preliminary evidence of efficacy, and identify specific patient subgroups that might derive particular benefits from the investigational treatment.
?:hasCUIAnnotation
?:hasGeneratedBy
?:type

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/C4521283_NCI>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/C4521283_NCI>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all